An observational study in Breast Cancer, sponsored by City of Hope Medical Center. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2025-12-05.
Sponsored by City of Hope Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Breast Neoplasms by City of Hope Medical Center — 17 open to participants now, 39 under way, 1 of them phase 3. Breast Neoplasms · City of Hope Medical Center.
Among the 89 studies in Breast Neoplasms by City of Hope Medical Center, this one is the 3rd largest by planned enrollment of the 12 observational ones that give a count, is one of 5 that started in 2010, is one of 12 observational ones, reaches primary completion later than 15 of the 38 other live ones, and was the 44th registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →17 of the 89 studies in Breast Neoplasms by City of Hope Medical Center are open now, in 1 country. Recruiting first, the newest first:
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only · Healthy volunteers
City of Hope Medical Center · Sites in United States
Ages 18+ · Women only
City of Hope Medical Center · Sites in United States
Ages 18+
City of Hope Medical Center · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 28 · Phase 3 1 · Phase 4 1
First in 1994; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 500 is above the median of 184 across 3,239 observational studies indexed under Breast Neoplasms.
Median enrollment 36 across the 76 interventional studies, 219 across the 12 observational. Of the 43 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
City of Hope Medical Center is the lead sponsor of 677 studies on the registry; 181 are open to participants now.
Of its 31 completed or terminated interventional studies of FDA-regulated products, 12 (39%) have results posted.
13 of the studies in Breast Neoplasms by City of Hope Medical Center that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04661982City of Hope Medical CenterLong Term Follow-Up in Patients With Stage 0-IIIC Breast Cancer | 2026-11-24 |
| NCT01992432City of Hope Medical CenterBrain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC) | 2026-11-30 |
| NCT01450020City of Hope Medical CenterPeer Navigator Education in Improving Survivorship Care in African American Breast Cancer Survivors | 2027-01-01 |
| NCT01824745City of Hope Medical CenterSurvivorship Care Planning in Improving the Quality of Life in Breast Cancer Survivors | 2027-01-01 |
| NCT07664579City of Hope Medical CenterInvestigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer | 2027-01-04 |
Add all 13 to your calendar (.ics) → With an account.
Among the 89 studies in Breast Neoplasms by City of Hope Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial studies long term follow-up care in patients with stage 0-IIIC breast cancer. Collecting feedback from breast cancer patients may help researchers to define comprehensive long term follow-up care for breast cancer survivors, better understand health-related quality of life and long-term complications in breast cancer survivors, and to increase the knowledge of the mechanisms by which a patient's own immune system attempts to combat breast cancer, and what factors may make this response more successful.
PRIMARY OBJECTIVES:
I. To provide comprehensive care to breast cancer survivors diagnosed with stage 0 to IIIC, who received at least part of their treatment at City of Hope.
II. To use the information obtained from follow-up of breast cancer survivors to describe the magnitude of risk and associated risk factors.
III. To use the information gained from follow-up of breast cancer survivors to describe health-related quality of life (HRQL) concerns in breast cancer survivors and identify those at highest risk.
OUTLINE:
Patients undergo long term follow-up and complete questionnaires.
Patients with stage 0-IIIC breast cancer
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients undergo long term follow-up and complete questionnaires.
Other: Long-term Follow-up · Other: Questionnaire Administration · Other: Quality-of-Life Assessment
Undergo long term follow-up
Also known as: LONG-TERM FOLLOW-UP, Long-term Follow-up
Ancillary studies
Ancillary studies
Also known as: Quality of Life Assessment
Incidence rates of the study end-points
Will estimation of incidence rates of the study end-points that may be associated with original diagnosis or treatment received, and delineation of temporal changes in serial measurements and their relationship to time-invariant characteristics such as original diagnosis, race, and education and time varying characteristics such as age and body mass index (BMI). Incidence rates may be compared with national standards adjusted for key demographic variables and between patient subgroups. Time of entry onto the study in the analysis will be from the date of diagnosis of primary disease. Stepwise logistic regression analysis of endpoints of interest at certain follow-up time may be conducted, accounting for the joint effect of such factors as age, time since diagnosis and treatment, radiation dose, chemotherapy and tumor subtype.
Time frame: Up to 12 years
FACT- Cog
Functional Assessment of Cancer Therapy Cognitive Function
Time frame: Change from pre-treatment baseline over a 2-year period
Cancer induced immune dysfunction
Will analyze patients' tumor, lymph node, and blood samples
Time frame: Up to 12 years
Started Jul 2010 (actual). Primary completion is estimated for Nov 2026, 196 months after the start.
Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 196 months is above that.
Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.